Semaglutide does appear to reduce inflammation, and the evidence goes beyond what you’d expect from weight loss alone. Across multiple clinical trials, semaglutide lowered C-reactive protein (a key marker of systemic inflammation) by 39% to 48% compared to placebo over about 16 months. These reductions show up in the liver, joints, blood vessels, and potentially even the brain.
How Semaglutide Reduces Inflammation
Semaglutide works by activating GLP-1 receptors, which are found not only in the gut and pancreas but also on immune cells. Macrophages, which are white blood cells that drive inflammation throughout the body, carry these receptors. When semaglutide activates them, it shifts macrophages from a pro-inflammatory state to an anti-inflammatory one. This shift reduces the number of immune cells migrating to inflamed tissue and increases the production of anti-inflammatory signaling molecules.
T-cells, another major player in the immune system, also respond to semaglutide. Activation of GLP-1 receptors on T-cells suppresses the release of several inflammatory compounds, including TNF-alpha and interferon-gamma, two of the most potent drivers of chronic inflammation. This happens through a signaling cascade that essentially dials down T-cell activation at its source.
There are two pathways at work here. The first is indirect: semaglutide causes significant fat loss, and excess body fat is itself an engine of chronic inflammation. The second is direct: semaglutide acts on immune cells regardless of weight changes. Animal research has shown that its protective effects on the heart exceed those of equivalent weight loss through dieting alone, suggesting the drug has genuine anti-inflammatory properties of its own.
What Happens to Inflammatory Markers
The most consistent finding across semaglutide trials is a dramatic drop in C-reactive protein (CRP), a blood marker that reflects inflammation throughout the body. In the large STEP trials involving adults with overweight or obesity, semaglutide at the 2.4 mg weekly dose reduced CRP by 44% in STEP 1, 39% in STEP 2, and 48% in STEP 3 compared to placebo, all measured at 68 weeks.
A separate trial in people living with HIV found that 32 weeks of semaglutide reduced CRP by about 48%, interleukin-6 (another inflammatory marker) by roughly 18%, and a marker of immune cell activation called soluble CD163 by about 10%. All of these changes were statistically significant, meaning they were very unlikely to be due to chance.
Liver Inflammation and Scarring
One of the strongest areas of evidence is in metabolic dysfunction-associated steatohepatitis (MASH), a condition where fat buildup in the liver triggers ongoing inflammation and eventually scarring (fibrosis). A phase 3 trial published in the New England Journal of Medicine found that 62.9% of patients taking semaglutide had their liver inflammation resolve without their scarring getting worse, compared to 34.3% on placebo. That’s nearly double the response rate.
Liver scarring itself also improved. About 37% of semaglutide patients had measurable reductions in fibrosis, compared to 22% on placebo. And roughly one-third of semaglutide patients achieved both goals: inflammation resolution and reduced scarring at the same time. These results were confirmed through liver biopsies, making them especially reliable.
Knee Pain and Joint Inflammation
A trial published in the New England Journal of Medicine tested semaglutide in 407 people with obesity and knee osteoarthritis who had moderate-to-severe pain. At the start, participants had an average pain score of about 71 on a 100-point scale. After 68 weeks, those on semaglutide saw their pain score drop by 41.7 points, compared to 27.5 points with placebo. Physical function scores also improved nearly twice as much in the semaglutide group.
While some of this improvement likely comes from reduced load on the joints through weight loss, the degree of pain relief exceeded what weight loss alone would typically explain. The reduction in systemic inflammation probably plays a contributing role, since osteoarthritis involves significant inflammatory activity in the joint lining.
Psoriasis and Skin Inflammation
Early clinical data in autoimmune skin disease is particularly striking. In a randomized trial of 31 patients who had both psoriasis and type 2 diabetes, 12 weeks of semaglutide treatment cut psoriasis severity scores (PASI) by 52.4%, compared to 22.8% in the control group. The median PASI score dropped from 21 to 10, a clinically meaningful improvement. Nearly half of the semaglutide group (46%) achieved a 90% or greater clearance of their psoriatic lesions, compared to just 7% in the control group.
Blood tests confirmed what the skin showed: CRP and interleukin-6 levels dropped significantly in the semaglutide group. Quality of life scores improved dramatically as well, with the median dermatology quality-of-life index falling from 14 to 4. This is a small study, and all participants also had diabetes and obesity, so it’s unclear how much of the benefit came from inflammation reduction versus metabolic improvements. But the speed and magnitude of the skin clearance suggest a direct anti-inflammatory contribution.
Cardiovascular Inflammation
The landmark SELECT trial, which enrolled over 17,000 people with obesity but without diabetes, demonstrated that semaglutide reduced the risk of major cardiovascular events like heart attacks and strokes. The mechanisms likely include both the reduction of excess body fat (which drives a pro-inflammatory, pro-clotting state) and direct effects of the drug on blood vessel inflammation. Semaglutide appears to reduce macrophage infiltration into arterial plaques, which is a key step in plaque rupture and heart attacks.
Brain Inflammation
Preclinical research suggests semaglutide can suppress inflammatory signaling in the brain, reduce oxidative damage, and support protective pathways that help neurons survive. Early human data has shown that semaglutide reduces cerebrospinal fluid levels of tau proteins and a neuroinflammation marker called YKL-40 in people with Alzheimer’s disease. It also appears to shift immune cell profiles in the brain toward a less inflammatory pattern.
The challenge is that semaglutide has limited ability to cross from the bloodstream into the brain. Some of it gets through, but whether enough reaches the brain to produce meaningful clinical benefits in neurodegenerative diseases remains an open question. Trials are underway, but no firm conclusions are possible yet.
How Quickly Inflammation Drops
Most clinical trials measuring inflammatory markers have assessed them at their endpoints, typically 32 to 68 weeks into treatment. The 32-week HIV trial showed significant reductions in CRP, interleukin-6, and immune activation markers by that point, suggesting meaningful anti-inflammatory effects within about eight months. The psoriasis trial showed substantial changes at just 12 weeks. The larger STEP trials captured their CRP reductions at 68 weeks (about 16 months).
Based on the available data, you can expect measurable drops in inflammatory markers within the first three to four months, with continued improvement over the following year. The timeline likely varies depending on how much of the anti-inflammatory effect comes from fat loss (which is gradual) versus direct immune modulation (which may be faster).